Q&A: How to jump-start new psychiatric and neurological drug development
Broad Institute
DECEMBER 18, 2023
Brain disorders are difficult to study and many drug candidates have failed in clinical trials, causing pharmaceutical companies to reduce their investments or even exit the field entirely. The key problem is that there appear to be many different underlying mechanisms that lead to depression. Biomarkers could take many forms.
Let's personalize your content